SVN-015 accepted into US NIDA funded programme

AI SummaryClose X

Solvonis Therapeutics plc announced that its novel compound SVN-015 has been accepted into the US National Institute on Drug Abuse's Addiction Treatment Discovery Program for methamphetamine and cocaine addiction, with NIDA funding early preclinical safety and efficacy studies. Successful completion could lead to non-dilutive NIH research grants of up to $3 million annually for five years, potentially funding human clinical trials. This marks an expansion of Solvonis' research into stimulant addictions, areas with significant unmet medical need and no approved drug treatments, impacting an estimated 3.0-3.2 million individuals across major markets.

Disclaimer*

UK 100

Latest directors dealings